CBChristopher John Bulpitt

Christopher John Bulpitt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher John Bulpitt has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers
    Open Access

    No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over

    by Jane Warwick, Emanuela Falaschetti, Kenneth Rockwood, Arnold Mitnitski, Lutgarde Thijs, Nigel Beckett, Christopher Bulpitt, Ruth Peters

    Treatment for hypertension with antihypertensive medication has been shown to reduce stroke, cardiovascular events, and mortality in older adults, but there is concern that such treatment may not be appropriate in frailer older adults. To investigate whether there is an interaction between effect of treatment for hypertension and frailty in older adults, we calculated the frailty index (FI) for all available participants from the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over, and obtained frailty adjusted estimates of the effect of treatment with antihypertensive medication on risk of stroke, cardiovascular events, and mortality. Participants in HYVET were randomised 1:1 to active treatment with indapamide sustained release 1.5 mg ± perindopril 2 to 4 mg or to matching placebo. Data relating to blood pressure, comorbidities, cognitive function, depression, and quality of life were collected at entry into the study and at subsequent follow-up visits. The FI was calculated at entry, based on 60 potential deficits. The distribution of FI was similar to that seen in population studies of adults aged 80 years and above (median FI, 0.17; IQR, 0.11–0.24). Cox regression was used to assess the impact of FI at entry to the study on subsequent risk of stroke, total mortality, and cardiovascular events. Models were stratified by region of recruitment and adjusted for sex and age at entry. Extending these models to include a term for a possible interaction between treatment for hypertension and FI provided a formula for the treatment effect as a function of FI. For all three models, the point estimates of the hazard ratios for the treatment effect decreased as FI increased, although to varying degrees and with varying certainty. We found no evidence of an interaction between effect of treatment for hypertension and frailty as measured by the FI. Both the frailer and the fitter older adults with hypertension appeared to gain from treatment. Further work to examine whether antihypertensive treatment modifies frailty as measured by the FI should be explored. ClinicalTrials.gov NCT00122811 (July 2005)


  • Mortality According to a Prior Assessment of Biological Age

    by Christopher Bulpitt, Riitta Antikainen, Hugh Markowe, Martin Shipley

    Measures of biological age have not been proven to predict mortality. This study examines whether measuring biological age improves the prediction of mortality. Prospective study from 1981 to 2001 of 397 male London Civil Servants. Two indices of biological ageing were calculated. 60 men died and both indices of biological ageing were related to survival. In a model that mutually adjusted for both chronological and biological age, biological age using index one was statistically significant with a hazard ratio (HR) of 1.11 per year of age (95% confidence interval 1.01 - 1.21, P=0.03). The useful components of the measures of biological ageing were systolic blood pressure (HR 1.31 for 1SD), albumin, and, to a lesser degree, Erythrocyte Sedimentation Rate (ESR). Greying of the hair, skin inelasticity, arcus senilis, and baldness were not predictors of mortality as measured by our methods. Similarly serum cholesterol, creatinine, calcium and urate could be excluded. A modified index was developed including systolic pressure, ESR, urea, albumin, and bilirubin and had a sensitivity of 78% and specificity of 51% in predicting subjects who died. This study represents 'proof of principle' in demonstrating the utility and validity of measuring biological age. The modified index needs to be tested prospectively.


  • Baseline characteristics of participants in the Hypertension in the Very Elderly Trial (HYVET)

    by Christopher John Bulpitt, Nigel Stanletanley Beckett, Ruth Peters, Winston Banya, Lisheng Liu, Ji‐Guang Wang, Vassil Stoyanovsky, Dan Dumitrascu, Yuri Nikitin, Jan Albertlbert Staessen, et al.

    The Hypertension in the Very Elderly Trial (HYVET) is a randomized double‐blind trial of active antihypertensive treatment (indapamide 1.5 mg sustained release ±2—4 mg perindopril) vs placebo in participants over the age of 80 years with a systolic blood pressure (SBP) of 160–199 mmHg during a placebo run‐in period plus a diastolic blood pressure (DBP) of<110 mmHg. The trial has completed with 3845 subjects randomized and we report the baseline characteristics. The participants were a healthy group. The numbers smoking, drinking alcohol and having previous cardiovascular events were low, and their hypertensive status was not usually associated with the metabolic syndrome; 1.0% of the whole group had a total cholesterol over 8.0 mmol/l, 1.1% a blood sugar over 11.1 mmol/l (irrespective of anti‐diabetic treatment) and 1.7% a serum urate over 460 μmol/l (women) and 0.6% over 520 μmol/l (men). A serum creatinine over 150 μmol/l excluded participants from the trial. The gender differences and age comparisons were as expected but the women had higher average total and high‐density‐lipoprotein‐cholesterol blood concentrations. Those with prior cardiovascular disease had an excess of the known cardiovascular risk factors. The baseline characteristics provide a basis for further understanding of the HYVET results, which have been published recently.


  • Open Access

    Smoking, dementia and cognitive decline in the elderly, a systematic review

    by Ruth Peters, Ruth Poulter, James Warner, Nigel Beckett, Lisa Burch, Chris Bulpitt

    Nicotine may aid reaction time, learning and memory, but smoking increases cardiovascular risk. Cardiovascular risk factors have been linked to increased risk of dementia. A previous meta-analysis found that current smokers were at higher risk of subsequent dementia, Alzheimer's disease, vascular dementia and cognitive decline.


  • Open Access

    Haemoglobin, anaemia, dementia and cognitive decline in the elderly, a systematic review

    by Ruth Peters, Lisa Burch, James Warner, Nigel Beckett, Ruth Poulter, Christopher Bulpitt

    Anaemia may increase risk of dementia or cognitive decline. There is also evidence that high haemoglobin levels increase risk of stroke, and consequently possible cognitive impairment. The elderly are more at risk of developing dementia and are also more likely to suffer from anaemia, although there is relatively little longitudinal literature addressing this association.


  • Open Access

    The use of orchids in Chinese medicine

    by Christopher J Bulpitt, Yan Li, Pauline F Bulpitt, Jiguang Wang

    In this article, the therapeutic uses of five Chinese medicines that contain orchids are discussed, together with a brief report of some of the animal experimentation undertaken. The impression that these preparations have no therapeutic use may be incorrect. However, herbal preparations have not usually been subject to the rigorous characterization and standardization necessary for clinical study, and persuading practitioners that substances in use for many centuries still need to be tested in randomized controlled clinical trials is proving a significant challenge.


  • Open Access

    Fracture risk and the use of a diuretic (indapamide sr) ± perindopril: a substudy of the Hypertension in the Very Elderly Trial (HYVET)

    by Christopher J Bulpitt, Ruth Peters, Jan A Staessen, Lutgarde Thijs, Marie-Christine De Vernejoul, Astrid E Fletcher, Nigel S Beckett

    The Hypertension in the Very Elderly Trial (HYVET) is a placebo controlled double blind trial of treating hypertension with indapamide Slow Release (SR) ± perindopril in subjects over the age of 80 years. The primary endpoints are stroke (fatal and non fatal). In view of the fact that thiazide diuretics and indapamide reduce urinary calcium and may increase bone mineral density, a fracture sub study was designed to investigate whether or not the trial anti-hypertensive treatment will reduce the fracture rate in very elderly hypertensive subjects. In the trial considerable care is taken to ascertain any fractures and to identify risk factors for fracture, such as falls, co-morbidity, drug treatment, smoking and drinking habits, levels of activity, biochemical abnormalities, cardiac irregularities, impaired cognitive function and symptoms of orthostatic hypotension. The trial is expected to provide 10,500 patient years of follow-up. Given a fracture rate of 40/1000 patient years and a 20% difference in fracture rate, the power of the sub study is 58% to detect this difference at the 5% level of significance. The corresponding power for a reduction of 25% is 78%. The trial is well under way, expected to complete in 2009, and on target to detect, if present, the above differences in fracture rate.


  • Open Access

    Secondary prevention of coronary heart disease in the elderly

    by Christopher J Bulpitt

    These anxieties arise from two main sources: firstly, there is little evidence from randomised controlled trials to guide our decisions in the very elderly (over 80s); and secondly they differ in many ways from younger subjects. Table 1 ⇓ lists some differences in major and minor categories. The list is far from complete. Pharmacological treatment or lifestyle changes may be inappropriate in the demented patient, weight loss is more often a problem than a therapeutic goal, and dietary change may be resisted as may the standard exercise regimens. If the patient has so many problems you do not know which to address first, the prescription of a drug for secondary prevention may not be the place to start. Nevertheless there are patients without serious co-morbidity, with good cognitive functioning, and who do not wish to have another cardiac ischaemic episode. We must decide what to advise these patients. This article considers strategies applicable to the chronic treatment of a patient with established CHD and does not address the issue of treatment in the acute situation.